Tenon Medical, Inc. (NASDQ:TNON), a company transforming care for patients suffering with certain sacroiliac joint disorders, announced Institutional Review Board (IRB) approval from WCG IRB for two separate Tenon-sponsored post market clinical studies of the Company’s Catamaran SI Joint Fusion System. The approval by WCG represents a milestone for Tenon, which allows designated Catamaran study centers to begin recruiting and enrolling patients into the respective studies.
The first approval from WCG IRB will support a prospective, multi-center, single arm post market study that will evaluate the clinical outcomes of patients with sacroiliac joint disruptions or degenerative sacroiliitis treated with the Catamaran SI Joint Fusion System. Patients will be followed out to 24 months assessing various patient reported outcomes, radiographic assessments, and adverse events.
Read more here
Don’t miss the next article from HealthFirst 100.
Join our mailing list to receive the latest posts from our blog directly in your inbox.